ITGAE and cancer: The ratio of anticancer DC1s to CD103loCD11b+ DCs was reduced from approximately 4: 1 in naïve mice to 1: 1 in both cancer models (Fig 3C), indicating that the number of CD103loCD11b+ DCs is similar to that of anticancer CD103+ DC1s following tumor development in the lung.